Buy Acomplia

Buy Acomplia Pill Slimming

Rimonabant has been past by many European countries for the treatment of obesity. It works differently than most other diet medications as well as has some possible benefits. Basically put, Rimonabant works by blocking receptors in the brain that are responsible for food cravings. When you’re eating less, it means generally you are consuming fewer calories and thus you lose weight. Some of the other potential benefits of this drug are that it has been shown to increase the “good” cholesterol while reducing “bad” cholesterol and has shown promise for helping smokers kick the habit [buy acomplia].While we don’t know all that went on in the FDA meeting, we do know that some of the issues that where brought up about this medication. One of the big obstacles they had issues with was its possible psychiatric side effects including suicidal influences. The FDA panel was not satisfied with the amount of feedback they had regarding this medication. And most likely they will keep an eye on it including watching the feedback coming in from other doctors around the world. It looks likely that a 50 month trail will then determine if this medication will be accepted into the USA market, a trail that would not be complete until 2010. The FDA had been scrutinized in the past for allowing drugs to hit the USA pharmacies in what some considered a too short of a study period [buy acomplia]. I suppose with such a possible popular medication such as Acomplia, that the FDA did not want to overlook all aspects of this medication before ever accepting it in the USA.
Obesity and overweight, weight reduction and weight management therapies, miracle weight loss pills are everywhere. Open the newspaper, switch on the T.V., pick up a magazine and you are sure to find ads and articles on the subject of weight loss and obesity [buy rimonabant].Weight loss and obesity are big business. Here are some factors that can make you rich if you happen to start a business related to weight management.
Two thirds of America is overweight. Out of that, 50 % are obese.300.000 premature deaths are caused by obesity [buy acomplia]. Obesity is the fastest growing epidemic in the world.Taking diet pills for obesity treatment has gradually become the trend in recent times. Obesity has become one huge problem that has affected all in the society; obese and non-obese alike. Obesity health problem has so affected the society that an industry has emerged from it – the weight loss supplement | diet pills industry.
Diet pills and supplements have taken over the nutritional need for well balanced and organic diet [buy acomplia]. The growing trend of taking diet pills is clear from the large variety of such pills and supplements flooding the market and the internet. Be that as it may, it will be simply presumptuous to believe that each of those diet pills can work miracles on your obesity. You must consider your peculiar situation and pick the best weight loss diet pills for you. Many organic [herbal-based] and synthetic weight loss diet pills are available for effective weight loss.

Why Treat Obesity With Acomplia?

Obesity is a disease that requires careful attention and pragmatic treatment. Lifestyle changes, exercising, dieting and weight loss are needed for a complete treatment and prevention of relapse. Diet pills can help in fighting obesity. However, a more sustainable approach to obesity treatment is required for a complete obesity cure [buy acomplia].
Obesity opens the body to other diseases that are worse than it. Conditions like heart attack, diabetes, high cholesterol levels, and the rest of them are the off-shoot of obesity. Obesity does not really cause them but they are exacerbated by the presence of obesity.

Rimonabant (Acomplia – Rimonabant) Successful Again in Reducing Weight, Waist European study says it also reduced factors for heart disease in obese people

April 15, 2005 – Acomplia – Rimonabant. which is still going by its generic name rimonabant, while it awaits FDA approval, has again won accolades for reducing bodyweight, waist circumference, and risk factors for heart disease in obese people, according to results of a randomized trial published in this week’s issue of The Lancet.

Luc Van Gaal (University Hospital Antwerp, Belgium) and colleagues undertook a trial (RIOEurope,buy acomplia) involving 1507 obese people from Europe and the USA.

Participants had a body mass index (BMI) of 30 kg/m 2or greater, or a BMI greater than 27 kg/m2with abnormal blood fat levels, high blood pressure, or both. They were randomly assigned 5mg or 20mg of a drug called rimonabant, or a placebo once daily in addition to a calorie controlled diet. The treatment groups had similar characteristics. 920 patients (61%) completed the one-year follow-up; 379 in the rimonabant 5mg group, 363 in the rimonabant 20mg group and 178 in the placebo group.(Buy Cheap Acomplia)

Weight loss at 1 year was greater in patients treated with 5 mg or 20 mg of rimonabant compared with placebo. More than 67% of patients who completed treatment with 20mg of rimonabant achieved 5% or more weight loss, and 39% achieved 10 % or more weight loss. Patients on 20 mg of rimonabant had greater improvements than placebo in waist circumference (average reduction of 4 cm), and cardiovascular risk factors including cholesterol, insulin resistance and prevalence of metabolic syndrome. The pattern of weight loss seen with rimonabant was sustained for around 36-40 weeks.

The most common side effects leading to study discontinuation were depressed mood disorders in all treatment groups; withdrawals due to nausea, vomiting, diarrhea, headache, dizziness, and anxiety were more frequent in the rimonabant 20 mg group than in other groups. Serious adverse events did not occur more frequently in patients treated with the drug than in those on placebo.

Professor Van Gaal concludes: “In this study, treatment with rimonabant over 1 year led to sustained, clinically meaningful weight loss, reduction in waist circumference, and associated improvements in several cardiovascular and metabolic risk factors.”

In an accompanying Comment Uberto Pagotto and Renato Pasquali (Buy Discount Acomplia on Sant Orsola-Malpighi General Hospital, Bologna, Italy) state: “These data, and those from the other ongoing clinical trials with rimonabant, might presumably help us to better tackle obesity and related metabolic and cardiovascular disease. When additional drugs are available, we will also have the possibility to individually target the therapeutic strategies according to phenotype characteristics and to the pathophysiological mechanism